(Date:12/14/2009)... JUPITER, Fla., Dec. 14 Dyadic International, ... it has extended its collaboration with The Scripps ... with Scripps to re-annotate the genome of Dyadic,s ... agreement is a continuation of the successful relationship ... 2006 when Dyadic engaged Scripps to annotate the ...
(Date:12/14/2009)... Dec. 14 Nektar Therapeutics (Nasdaq: ... been appointed to serve on its board of ... leader with over 35 years of experience in ... brings to Nektar extensive industry perspective at an ... W. Robin, President and CEO of Nektar and ...
(Date:12/11/2009)... (Nasdaq: DNDN ) announced today that the ... exercised in full their option to purchase an ... public offering price of $24.75 per share. ... of the offering to an aggregate of 17,250,000 ... receive net proceeds from the offering of approximately ...
(Date:12/11/2009)... ASA (OSE: ALGETA), the,cancer therapeutics company, announces ... the Tulane Cancer Center, New Orleans, has ... study of Alpharadin in men with,castration-resistant (also ... metastasized to the skeleton. , ... Prostate CAncer) study is a,double-blind, randomized, controlled ...
Breaking Biology Technology:Dyadic International Extends Collaboration With The Scripps Research Institute 2Dyadic International Extends Collaboration With The Scripps Research Institute 3Dyadic International Extends Collaboration With The Scripps Research Institute 4Dyadic International Extends Collaboration With The Scripps Research Institute 5Dennis Winger Joins Nektar Therapeutics' Board of Directors 2Dennis Winger Joins Nektar Therapeutics' Board of Directors 3Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 3Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 3Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 4... Position -, HOPKINTON, Mass., Oct. 29 Caliper ... of tools and services for,drug discovery and life sciences ... sell its Pharmaceutical Development & Quality,Analysis (PDQ) product line ... million. The PDQ product line consists of products used,for ...
... Myers, Inc.,(NYSE: RBN ) announced today that its ... Board of Directors, increasing the size from,seven to eight ... for election at the January 7, 2009 annual shareholder ... board., Richard J. Giromini, 55, is President and ...
... Trubion Pharmaceuticals Inc.,(Nasdaq: TRBN ) today announced ... the company at two upcoming industry and/or investor,conferences:, ... Conference at the,New York Palace Hotel, 455 Madison Ave. ... senior vice president, is scheduled to present,at 9:55 a.m. ...
Other Biology Technology:Caliper Enters Agreement to Divest Non-Core Pharmaceutical Development & Quality Analysis Product Line 2Caliper Enters Agreement to Divest Non-Core Pharmaceutical Development & Quality Analysis Product Line 3Robbins & Myers, Inc. Elects New Board Members 2Trubion Announces Presentations at Upcoming Investor Conferences 2ID clarifier: With ethidium bromide (50 μg/ml)...
... C2C12 cells were cultured in DMEM and harvested ... order to keep the antigens in their native ... cells are arrayed on a 12-well (5 mm) ... treated to enhance cellular attachment and to minimize ...
... for optimal colony growth; ... growth of anchorage-dependent cells. ... colony-forming assays of human ... Not suitable for long-term ...
... is a convenient, premixed, formamide-containing ... and Perfect RNA Markers. This ... dilution and is suitable for ... mix equal volumes of RNA ...
Biology Products:Biology NavigationMedical Navigation